Pyrazolopyrimidine compounds as jak inhibitors

A compound, C1-C6 technology, used in organic chemistry, drug combinations, medical preparations containing active ingredients, etc., can solve problems such as defective signal transduction

Pending Publication Date: 2020-08-25
F HOFFMANN LA ROCHE & CO AG
View PDF22 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Consistent with this, primary cells derived from TYK2-deficient humans ar

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyrazolopyrimidine compounds as jak inhibitors
  • Pyrazolopyrimidine compounds as jak inhibitors
  • Pyrazolopyrimidine compounds as jak inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example

[0258] General Experimental Details

[0259] All solvents and commercially available reagents were used as received unless otherwise stated. In the case of product purification by silica gel chromatography, a glass column manually packed with silica gel (Kieselgel 60, 220-440 mesh, 35-75 μm) was used or A SPE Si II column was used for this operation. "Isolute SPE Si column" refers to the column containing 50μμm average particle size and nominal Prepacked polypropylene column of unbonded reactive silica with irregular particles of porosity. currently using In the case of the SCX-2 column, " "SCX-2 column" refers to a prepacked polypropylene column containing an unblocked propylsulfonic acid functionalized silica strong cation exchange sorbent.

[0260] LCMS conditions

[0261] Method A (LCMS15)

[0262] The experiment was carried out on SHIMADZU 20A HPLC, using C18 reverse phase column (50x 3mm Shim-Pack XR-ODS, 2.2μm particle size), the eluent was: solvent A: water ...

example 2

[0411] Example 2: First fraction, RT 1 =19.63min; 41.9mg white solid (S)-N-[3-[5-chloro-2-(difluoromethoxy)phenyl)-1-(1-methyl-2-oxopyrrolidine- 3-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; LC / MS (Method F, ESI): [M+H] + =502.2,R T =1.63min, 1 H NMR (400MHz, DMSO-d 6 ): δ(ppm)9.76(s,1H),9.36(dd,J=6.8,1.6Hz,1H),8.70–8.69(m,2H),8.43(s,1H),7.65(dd,J=8.8 ,2.4Hz,1H),7.59(d,J=2.4Hz,1H),7.46(d,J=8.8Hz,1H),7.31(dd,J=7.2,4.4Hz,1H),7.27(t,J =73.2Hz, 1H), 5.29–5.25(m, 1H), 3.54–3.51(m, 1H), 3.45–3.42(m, 1H), 2.83(s, 3H), 2.60–2.55(m, 2H).

example 3

[0412] Example 3: Second fraction, RT2 = 24.74min; 40.1 mg white solid (R)-N-[3-[5-chloro-2-(difluoromethoxy)phenyl)-1-(1-methan yl-2-oxopyrrolidin-3-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; LC / MS (Method F, ESI): [M+H] + =502.2,R T = 1.61min, 1 H NMR (300MHz, DMSO-d 6 ): δ(ppm)9.76(s,1H),9.36(dd,J=6.8,1.6Hz,1H),8.70–8.69(m,2H),8.43(s,1H),7.65(dd,J=8.8 ,2.4Hz,1H),7.59(d,J=2.4Hz,1H),7.46(d,J=8.8Hz,1H),7.31(dd,J=7.2,4.4Hz,1H),7.27(t,J =73.2Hz, 1H), 5.29–5.25(m, 1H), 3.54–3.51(m, 1H), 3.45–3.42(m, 1H), 2.83(s, 3H), 2.60–2.55(m, 2H).

[0413] General Method 3: Examples 4 and 5

[0414]

[0415] N-(3-(5-chloro-2-(difluoromethoxy)phenyl)-1-(2-oxopyrrolidin-3-yl)-1H-pyrazol-4-yl)pyrazolo [1,5-a]pyrimidine-3-carboxamide (isomer 1) and

[0416] N-(3-(5-chloro-2-(difluoromethoxy)phenyl)-1-(2-oxopyrrolidin-3-yl)-1H-pyrazol-4-yl)pyrazolo [1,5-a]pyrimidine-3-carboxamide (isomer 2)

[0417] To a solution of Intermediate A (100 mg, 0.247 mmol) in DMF (10 mL) ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Description

[0001] Cross References to Related Applications [0002] This patent application claims the benefit of priority from International Patent Application PCT / CN2018 / 072568 filed on January 15, 2018, the entire content of which is incorporated herein by reference. technical field [0003] The present invention relates to Janus kinase (such as JAK1) inhibitor compounds, compositions comprising these compounds, and methods of use including, but not limited to, diagnosing or treating a patient suffering from a condition responsive to inhibition of a JAK kinase. Background technique [0004] Cytokine pathways mediate a wide range of biological functions, including many aspects of inflammation and immunity. Janus kinases (JAKs), including JAK1, JAK2, JAK3, and TYK2, are cytoplasmic protein kinases that associate with type I and type II cytokine receptors and regulate cytokine signal transduction. Binding of cytokines to cognate receptors triggers activation of receptor-associated JAK...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D487/04A61P37/00A61P11/06A61K31/519
CPCC07D487/04A61P37/00A61P11/06C07D519/00G06V20/53G06F3/147G06M11/00G08G1/005G08G1/04G09G2380/06H04N7/181H04N7/188
Inventor M·扎克P·吉本斯Y-X·程S·C·格达克里
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap